Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline

Background The identification of variants in genes involved in nicotine metabolism may have implications for the pharmacological therapy of smoking. In the scenario of precision medicine, the aim of this study was to evaluate a possible association of cytochrome P450 2A6 and 2B6 polymorphisms with varenicline pharmacotherapy. Methods The present study included 167 patients treated with varenicline in monotherapy who were from a cohort study of 1049 patients (treated with smoking cessation drugs: nicotine replacement therapy, bupropion, varenicline, or combinations of same). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. The CYP2A6 rs1801272 and rs28399433 and CYP2B6 rs8109525 polymorphisms were genotyped by real-time PCR using the TaqMan (R) platform. Results Patients with AG or GG genotypes for CYP2B6 rs8109525 had a higher success rate of smoking cessation with varenicline (51.2%) compared with carriers of the AA genotypes (33.3%, P = 0.03, n = 167). The AG or GG genotypes were also associated with a higher odds ratio of success, even in a multivariate analysis adjusting for potential confounders (OR = 2.01; 95%CI = 1.01 to 4.00; P = 0.047). Conclusion CYP2B6 rs8109525 was associated with a higher success rate of smoking cessation with varenicline treatment. This finding may be useful in pharmacogenomic strategies for smoking cessation therapy.

Palavras-chave

Nicotine metabolism, Smoking cessation, Polymorphism, rs8109525

URI

https://observatorio.fm.usp.br/handle/OPI/34334

Referências

Allenby CE, 2016, J NEUROIMMUNE PHARM, V11, P471, DOI 10.1007/s11481-016-9656-y
Bibi Z, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-27
Bloom AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079700
Bloom AJ, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.468
Chatkin José Miguel, 2006, J. bras. pneumol., V32, P573, DOI 10.1590/S1806-37132006000600016
Chenoweth MJ, 2017, TRENDS PHARMACOL SCI, V38, P55, DOI 10.1016/j.tips.2016.09.006
Fiore M. C., 2008, TREATING TOBACCO USE
Fiore MC, 2000, TREATING TOBACCO USE
Henningfield JE, 1998, FOOD DRUG LAW J, V53, P75
Hiroi N, 2009, MOL PSYCHIATR, V14, P653, DOI 10.1038/mp.2009.16
Ho MK, 2007, PHARMACOGENOMICS J, V7, P81, DOI 10.1038/sj.tpj.6500436
Issa JS, 2014, INT J CARDIOL, V172, P485, DOI 10.1016/j.ijcard.2014.01.055
Issa JS, 2013, NICOTINE TOB RES, V15, P1146, DOI 10.1093/ntr/nts230
King DP, 2012, NEUROPSYCHOPHARMACOL, V37, P641, DOI 10.1038/npp.2011.232
Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI 10.1038/nrn1298
Lerman C, 2015, LANCET RESP MED, V3, P131, DOI 10.1016/S2213-2600(14)70294-2
Lopez-Flores Luis A., 2017, Data in Brief, V15, P86, DOI 10.1016/j.dib.2017.09.013
Marinho IM, 2018, REV BRAS ANESTESIOL, V68, P344, DOI [10.1016/j.bjan.2017.12.007, 10.1016/j.bjane.2017.12.004]
Perez-Rubio G, 2017, GENE, V628, P205, DOI 10.1016/j.gene.2017.07.051
Ribeiro S A, 1999, Rev Assoc Med Bras (1992), V45, P39
Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438
Sarginson JE, 2011, AM J MED GENET B, V156B, P275, DOI 10.1002/ajmg.b.31155
Scholz J, 2016, ONCOTARGET, V7, P30032, DOI 10.18632/oncotarget.9090
Sieminska A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1455-5
Silva AP, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-015-0180-4
Slemmer JE, 2000, J PHARMACOL EXP THER, V295, P321
Sofuoglu M, 2012, NEUROPSYCHOPHARMACOL, V37, P1509, DOI 10.1038/npp.2011.336
Tang DW, 2012, NEUROIMAGE, V60, P2136, DOI 10.1016/j.neuroimage.2012.01.119
Volkow ND, 2005, AM J PSYCHIAT, V162, P1401, DOI 10.1176/appi.ajp.162.8.1401
World Health Organization, 2015, WHO REP GLOB TOB EP
Tomaz PRX, 2018, BMC MED GENET, V19, DOI 10.1186/s12881-018-0571-3
Tomaz PRX, 2015, EUR J CLIN PHARMACOL, V71, P1067, DOI 10.1007/s00228-015-1896-x

Coleções

Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/13

Página do item completo